Answers are grounded in this paper and cite their sources.
Recent studies on thiazolide antivirals have identified compounds RM5038 and RM5021 as potent inhibitors of hepatitis B virus (HBV), hepatitis C virus (HCV), and influenza A, although their development has been limited by poor aqueous solubility and rapid metabolic clearance. In this work, a series of novel halogen-substituted and 4'-alkylsulfone thiazolide analogs were synthesized using updated convergent synthetic approaches and flexible protecting group strategies. DMPK evaluation demonstrated that 3-X halogen substitution significantly improved aqueous solubility in parallel to enhancing metabolic stability. Within the chlorothiazolide series, compounds 10gand 10l displayed much improved metabolic stability profiles, excellent aqueous solubility representing a 10-fold improvement over the parent drug, together with low single-digit micromolar antiviral (influenza A) activity and acceptable in vitro safety indices. Evaluation of the 4'-alkylsulfone thiazolides also revealed improved in vitro DMPK profiles while retaining micromolar antiviral potency. SAR analysis indicated that short alkyl sulfone substituents containing two to three carbons are optimal for antiviral activity, while branched alkyl groups may provide additional metabolic advantages. In summary, compounds 10g, 10l, and 15d represent promising early leads for progression to in vivo profiling and additional preclinical evaluation.
No takes yet. Share an insight, caveat, or question.
Taujanskas et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: